As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2023 about Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Q&A for Industry can be found below.